Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 15Gastrointestinal 7Genitourinary 6Endocrine 6Tumor-Agnostic 4Head & Neck 3Sarcoma 2Other solid neoplasm 2Other hematologic neoplasm 2NET 2Thoracic 1Other neoplasm 1Lymphoid 1Gynecologic 1Dermatologic 1CNS 1

Conditions

Hormone Receptor Positive Malignant Neoplasm of Breast 1

Interventions

Cyclophosphamide 5Decitabine 3Carboplatin 3Busulfan 3Radiotherapy 2Endoscopy 2Chemoradiotherapy 2Capecitabine 2sintilimab 1sargramostim 1liposomal doxorubicin 1fludarabine phosphate 1exemestane 1camrelizumab 1alethine 1Watchful Waiting 1Vincristine 1Ultrasonography, Doppler 1Rifampin 1Proton Therapy 1Polymerase Chain Reaction 1Patient Reported Outcome Measures 1Papanicolaou Test 1Paclitaxel 1Observation 1Mycophenolic Acid 1Methylation 1Mass Spectrometry 1Liver Transplantation 1Laparoscopy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Everolimus × Other neoplasm × Clear all
NCT02025712 2014-01-01

Exemestane Plus Everolimus for Hormone-receptor Positive Metastatic Breast Cancer

Organisation for Oncology and Translational Research

Phase 2 Unknown
35 enrolled
BreastOther neoplasm

Hormone Receptor Positive Malignant Neoplasm of Breast

Data powered by HemOnc (CC BY 4.0) Colophon âš¡